Jaguar Animal Health (JAGX) Projected to Post Quarterly Earnings on Thursday

Jaguar Animal Health (NASDAQ:JAGX) is expected to be issuing its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect the company to announce earnings of ($149.10) per share and revenue of $4.21 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 21, 2026 at 4:15 PM ET.

Jaguar Animal Health Trading Up 10.0%

Shares of Jaguar Animal Health stock opened at $3.30 on Tuesday. The firm has a market capitalization of $1.22 million, a PE ratio of 0.00 and a beta of 0.01. The company has a current ratio of 0.50, a quick ratio of 0.29 and a debt-to-equity ratio of 4.08. The firm’s 50 day moving average is $14.16 and its 200 day moving average is $31.06. Jaguar Animal Health has a 1 year low of $2.53 and a 1 year high of $312.63.

Wall Street Analysts Forecast Growth

JAGX has been the topic of several research reports. Wall Street Zen raised shares of Jaguar Animal Health from a “strong sell” rating to a “sell” rating in a report on Sunday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $2,100.00.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.